IL238403B - Methods and preparations for the treatment of progesterone-dependent conditions - Google Patents
Methods and preparations for the treatment of progesterone-dependent conditionsInfo
- Publication number
- IL238403B IL238403B IL238403A IL23840315A IL238403B IL 238403 B IL238403 B IL 238403B IL 238403 A IL238403 A IL 238403A IL 23840315 A IL23840315 A IL 23840315A IL 238403 B IL238403 B IL 238403B
- Authority
- IL
- Israel
- Prior art keywords
- compositions
- methods
- dependent conditions
- treating progesterone
- progesterone
- Prior art date
Links
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title 2
- 230000001419 dependent effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229960003387 progesterone Drugs 0.000 title 1
- 239000000186 progesterone Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261722095P | 2012-11-02 | 2012-11-02 | |
| PCT/US2013/066095 WO2014070517A1 (en) | 2012-11-02 | 2013-10-22 | Methods and compositions for treating progesterone-dependent conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL238403A0 IL238403A0 (en) | 2015-06-30 |
| IL238403B true IL238403B (en) | 2019-01-31 |
Family
ID=49510593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL238403A IL238403B (en) | 2012-11-02 | 2015-04-21 | Methods and preparations for the treatment of progesterone-dependent conditions |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9545411B2 (OSRAM) |
| EP (1) | EP2914268B1 (OSRAM) |
| JP (2) | JP6343619B2 (OSRAM) |
| CN (1) | CN104755087A (OSRAM) |
| AU (1) | AU2013338305B2 (OSRAM) |
| CA (1) | CA2888377C (OSRAM) |
| ES (1) | ES2688821T3 (OSRAM) |
| HK (1) | HK1211852A1 (OSRAM) |
| IL (1) | IL238403B (OSRAM) |
| MX (1) | MX2015004821A (OSRAM) |
| WO (1) | WO2014070517A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46298A (fr) * | 2015-05-18 | 2019-07-31 | Bayer Pharma AG | Modulateur sélectif du récepteur de la progestérone (sprm) pour son utilisation dans le traitement des saignements menstruels abondants |
| US20190008804A1 (en) * | 2016-01-12 | 2019-01-10 | Repros Therapeutics Inc. | Trans-Clomiphene and Progesterone Receptor Antagonist Combination Therapy for Treating Hormone-Dependent Conditions |
| KR20210134927A (ko) | 2019-02-28 | 2021-11-11 | 얀센 바이오테크 인코포레이티드 | 화농성 한선염의 치료를 위한 항-il-알파 항체 |
| MX2022012967A (es) | 2020-04-16 | 2023-01-18 | Janssen Biotech Inc | Tratamiento de la hidradenitis supurativa. |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2377418A1 (fr) | 1977-01-13 | 1978-08-11 | Roussel Uclaf | Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments |
| FR2521565B1 (fr) | 1982-02-17 | 1985-07-05 | Dior Sa Parfums Christian | Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees |
| FR2522328B1 (fr) | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2534487B1 (fr) | 1982-10-15 | 1988-06-10 | Dior Christian Parfums | Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede |
| WO1985002092A1 (en) | 1983-11-14 | 1985-05-23 | Bio-Mimetics Inc. | Bioadhesive compositions and methods of treatment therewith |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US4954490A (en) | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| US5077211A (en) | 1988-07-06 | 1991-12-31 | Applied Genetics, Inc. | Purification and administration of dna repair enzymes |
| US5468741A (en) | 1993-05-28 | 1995-11-21 | The Regents Of The University Of California | Use of low levels of mifepristone to treat leiomyomata |
| US5543150A (en) | 1993-09-15 | 1996-08-06 | Columbia Laboratories, Inc. | Method of progesterone delivery and affect thereof |
| DE4426601A1 (de) | 1994-07-27 | 1996-02-01 | Schering Ag | Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri |
| EP0806952B1 (de) | 1995-02-02 | 2003-04-02 | Schering Aktiengesellschaft | Verwendung von kompetitiven progesteronantagonisten für die herstellung von arzneimitteln zur behandlung von dysfunktionellen uterinen blutungen |
| EP0900234B1 (en) | 1996-05-01 | 2000-07-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 21-substituted progesterone derivatives as new antiprogestational agents |
| US6900193B1 (en) | 1996-05-01 | 2005-05-31 | The United States Of America As Represented By The Department Of Health And Human Services | Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| WO1998008471A1 (en) | 1996-08-30 | 1998-03-05 | The Population Council, Inc. | Vaginal application mifepristone |
| US6682174B2 (en) | 1998-03-25 | 2004-01-27 | Silverbrook Research Pty Ltd | Ink jet nozzle arrangement configuration |
| US6020328A (en) | 1998-03-06 | 2000-02-01 | Research Triangle Institute | 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| EP1008443A1 (de) | 1998-12-08 | 2000-06-14 | Alusuisse Technology & Management AG | Sterilisierbarer Folienverbund für Verpackungszwecke |
| US6740645B1 (en) | 1999-09-03 | 2004-05-25 | Research Triangle Institute | 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties |
| UA74168C2 (uk) | 1999-10-05 | 2005-11-15 | Коламбіа Леборетеріс (Бермуда) Лімітед | Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу |
| CA2403756C (en) | 2000-03-17 | 2010-02-09 | Hyun K. Kim | Structural modification of 19-norprogesterone i: 17-.alpha.-substituted, 11-.beta.-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents |
| IN191020B (OSRAM) | 2000-03-28 | 2003-09-13 | Dabur Res Foundation | |
| AU1824302A (en) | 2000-10-18 | 2002-04-29 | Schering Ag | Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| WO2003005954A2 (en) | 2001-07-09 | 2003-01-23 | Zonagen, Inc. | Methods and materials for the treatment of testosterone deficiency in men |
| JP4898431B2 (ja) | 2003-04-29 | 2012-03-14 | ザ ジェネラル ホスピタル コーポレイション | 複数薬物の持続放出のための方法およびデバイス |
| EP1593376A1 (en) | 2004-05-04 | 2005-11-09 | Warner-Lambert Company LLC | Improved pullulan capsules |
| NZ552720A (en) | 2004-07-09 | 2010-02-26 | Population Council Inc | Sustained release compositions containing progesterone receptor modulators |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| AU2006227243B2 (en) | 2005-03-22 | 2011-10-27 | Allergan pharmaceuticals International Ltd. | Dosing regimes for trans-clomiphene |
| JP2008536910A (ja) | 2005-04-20 | 2008-09-11 | ファイザー・リミテッド | プロゲステロン受容体アンタゴニストとしてのピラゾール誘導体 |
| DE102005030294A1 (de) | 2005-06-24 | 2007-01-04 | Schering Ag | Nichtsteroidale Progesteronrezeptor-Modulatoren |
| EP1940413A1 (en) | 2005-09-29 | 2008-07-09 | Repros Therapeutics Inc. | Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride |
| CN1846703A (zh) | 2006-02-13 | 2006-10-18 | 程定超 | 米非司酮阴道给药制剂及其组成和制备方法 |
| US8173626B2 (en) * | 2006-03-08 | 2012-05-08 | Danco Laboratories Llc | Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders |
| CA2673128C (en) | 2006-10-24 | 2018-07-03 | Repros Therapeutics Inc. | Compositions and methods for suppressing endometrial proliferation |
| JP5379121B2 (ja) | 2007-04-05 | 2013-12-25 | ユニバーシティ・オブ・カンザス | プルランを含む速溶性医薬組成物 |
| US8569274B2 (en) | 2007-04-20 | 2013-10-29 | Preglem S.A. | Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding |
| JP5555631B2 (ja) | 2007-09-20 | 2014-07-23 | ラピドット メディカル インポート アンド マーケティング リミテッド | ミフェプリストンによる子宮平滑筋腫、平滑筋腫、筋腫、子宮類線維腫、子宮内膜症、または腺筋症を治療するための組成物および手段 |
| TWI477276B (zh) * | 2008-04-28 | 2015-03-21 | Repros Therapeutics Inc | 抗黃體素給藥方案 |
| JP5992330B2 (ja) | 2009-09-29 | 2016-09-14 | メディメトリクス ペルソナリズド ドルグ デリヴェリー ベー ヴェ | 物質を投与するための子宮内電子カプセル |
| UA113283C2 (xx) * | 2010-12-23 | 2017-01-10 | 19-норстероїди і їх застосування для лікування прогестеронзалежних станів | |
| WO2012121767A1 (en) * | 2011-03-09 | 2012-09-13 | Arstat, Inc. | Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування |
-
2013
- 2013-10-22 US US14/440,023 patent/US9545411B2/en not_active Expired - Fee Related
- 2013-10-22 JP JP2015540700A patent/JP6343619B2/ja not_active Expired - Fee Related
- 2013-10-22 CN CN201380057256.XA patent/CN104755087A/zh active Pending
- 2013-10-22 MX MX2015004821A patent/MX2015004821A/es unknown
- 2013-10-22 AU AU2013338305A patent/AU2013338305B2/en not_active Ceased
- 2013-10-22 HK HK15112776.8A patent/HK1211852A1/xx unknown
- 2013-10-22 ES ES13783818.1T patent/ES2688821T3/es active Active
- 2013-10-22 CA CA2888377A patent/CA2888377C/en not_active Expired - Fee Related
- 2013-10-22 EP EP13783818.1A patent/EP2914268B1/en active Active
- 2013-10-22 WO PCT/US2013/066095 patent/WO2014070517A1/en not_active Ceased
-
2015
- 2015-04-21 IL IL238403A patent/IL238403B/en active IP Right Grant
-
2018
- 2018-01-25 JP JP2018010276A patent/JP2018062530A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20150297612A1 (en) | 2015-10-22 |
| AU2013338305A1 (en) | 2015-05-14 |
| AU2013338305B2 (en) | 2018-06-07 |
| MX2015004821A (es) | 2015-08-14 |
| HK1211852A1 (en) | 2016-06-03 |
| IL238403A0 (en) | 2015-06-30 |
| CA2888377C (en) | 2021-02-02 |
| JP2015535282A (ja) | 2015-12-10 |
| EP2914268A1 (en) | 2015-09-09 |
| CA2888377A1 (en) | 2014-05-08 |
| ES2688821T3 (es) | 2018-11-07 |
| EP2914268B1 (en) | 2018-07-04 |
| CN104755087A (zh) | 2015-07-01 |
| WO2014070517A1 (en) | 2014-05-08 |
| US9545411B2 (en) | 2017-01-17 |
| JP6343619B2 (ja) | 2018-06-13 |
| JP2018062530A (ja) | 2018-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL238416A0 (en) | Preparations and methods for the treatment of diseases caused by protein pathology | |
| SMT201700595T1 (it) | Composizioni e metodi per trattare il cancro | |
| IL246023B (en) | Methods and preparations for the treatment of age-related conditions | |
| ZA201502880B (en) | Compositions and methods for immunotherapy | |
| DK3292875T3 (en) | Compositions and methods for treating diseases | |
| IL227429A0 (en) | The components and methods of cancer treatment | |
| ZA201408594B (en) | Xylitol-based anti-mucosal compositions and related methods and compositions | |
| EP2922861A4 (en) | BIOMARKER COMPOSITIONS AND METHODS | |
| EP2823306A4 (en) | BIOMARKER COMPOSITIONS AND METHODS | |
| IL234829A0 (en) | Methods and preparations for treating inflammation | |
| ZA201404676B (en) | Compositions and methods for treating metabolic disorders | |
| ZA201404187B (en) | Compositions and methods for treating dental conditions | |
| HUE044816T2 (hu) | Készítmények és eljárások hajhullás kezelésére | |
| EP2806872A4 (en) | BENDAMUSTIN COMPOSITIONS AND RELATED METHODS | |
| IL233968A (en) | Compounds and preparations containing them for the treatment of fibrosis | |
| TWI559917B (en) | Methods and compositions for treating neurodegenerative diseases | |
| IL232648A0 (en) | Preparations and methods for treating glioma | |
| GB201315350D0 (en) | Methods and compositions | |
| IL229231A0 (en) | Preparations and methods for the treatment of cancer | |
| GB201315347D0 (en) | Methods and compositions | |
| IL238403A0 (en) | Methods and preparations for the treatment of progesterone-dependent conditions | |
| IL239426A0 (en) | Methods and compositions of biomarkers | |
| GB201206859D0 (en) | Method and composition | |
| EP2841102A4 (en) | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER | |
| ZA201308683B (en) | Methods and compositions suitable for preventing and treating hyperleptinemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |